JP7725511B2 - ４－アミノキナゾリン化合物 - Google Patents

４－アミノキナゾリン化合物

Info

Publication number
JP7725511B2
JP7725511B2 JP2022580703A JP2022580703A JP7725511B2 JP 7725511 B2 JP7725511 B2 JP 7725511B2 JP 2022580703 A JP2022580703 A JP 2022580703A JP 2022580703 A JP2022580703 A JP 2022580703A JP 7725511 B2 JP7725511 B2 JP 7725511B2
Authority
JP
Japan
Prior art keywords
methyl
cyclopropyl
oxy
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022580703A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022173033A5 (https=
JPWO2022173033A1 (https=
Inventor
賢一 川口
和幸 倉本
智禎 今泉
貴裕 森川
光晶 奥村
直 ▲今▼田
英次 河南
亮 佐藤
陽平 関
壽雄 濱口
裕貴 石岡
裕樹 福留
生実 栗脇
建之 長島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JPWO2022173033A1 publication Critical patent/JPWO2022173033A1/ja
Publication of JPWO2022173033A5 publication Critical patent/JPWO2022173033A5/ja
Application granted granted Critical
Publication of JP7725511B2 publication Critical patent/JP7725511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022580703A 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物 Active JP7725511B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物

Publications (3)

Publication Number Publication Date
JPWO2022173033A1 JPWO2022173033A1 (https=) 2022-08-18
JPWO2022173033A5 JPWO2022173033A5 (https=) 2024-02-08
JP7725511B2 true JP7725511B2 (ja) 2025-08-19

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580703A Active JP7725511B2 (ja) 2021-02-15 2022-02-14 ４－アミノキナゾリン化合物

Country Status (12)

Country Link
US (1) US20240150366A1 (https=)
EP (1) EP4293025B1 (https=)
JP (1) JP7725511B2 (https=)
KR (1) KR20230145360A (https=)
CN (1) CN116867788A (https=)
AU (1) AU2022219651A1 (https=)
CA (1) CA3211110A1 (https=)
ES (1) ES3054794T3 (https=)
MX (1) MX2023009520A (https=)
PL (1) PL4293025T3 (https=)
SA (1) SA523450286B1 (https=)
WO (1) WO2022173033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008849A (es) 2022-01-21 2024-07-25 Usynova Pharmaceuticals Ltd Compuestos de benzopirimidina y uso de estos.
AU2023231912A1 (en) * 2022-03-11 2024-08-15 Astellas Pharma Inc. Heterocyclic compound for inducing degradation of g12d mutant kras protein
JP7733274B1 (ja) * 2022-08-12 2025-09-02 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
AR130192A1 (es) * 2022-08-12 2024-11-13 Astellas Pharma Inc Combinaciones antineoplásicas que comprenden quimioterapia
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250114339A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor
AU2024357850A1 (en) 2023-10-09 2026-04-23 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
US20220363681A1 (en) * 2019-08-16 2022-11-17 Genfleet Therapeutics (Shanghai) Inc. Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018143315A1 (ja) 2017-02-02 2018-08-09 アステラス製薬株式会社 キナゾリン化合物

Also Published As

Publication number Publication date
EP4293025A4 (en) 2025-02-26
SA523450286B1 (ar) 2024-06-12
AU2022219651A1 (en) 2023-09-07
US20240150366A1 (en) 2024-05-09
MX2023009520A (es) 2023-08-24
EP4293025B1 (en) 2025-10-29
EP4293025C0 (en) 2025-10-29
JPWO2022173033A1 (https=) 2022-08-18
PL4293025T3 (pl) 2026-02-16
WO2022173033A1 (ja) 2022-08-18
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
CN116867788A (zh) 2023-10-10
ES3054794T3 (en) 2026-02-06
KR20230145360A (ko) 2023-10-17

Similar Documents

Publication Publication Date Title
JP7725511B2 (ja) ４－アミノキナゾリン化合物
JP7169729B1 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
JP6587116B2 (ja) キナゾリン化合物
JP7440710B1 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクに作用する複素環化合物
US11447492B2 (en) ERBB receptor inhibitors
CA3255513A1 (en) HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
WO2022037568A1 (en) Bicyclic compounds, compositions and use thereof
WO2024034591A1 (ja) Ｋｒａｓタンパクを阻害及び／又は分解誘導するための複素環化合物
CN111936499A (zh) Mat2a的杂二环抑制剂和用于治疗癌症的方法
WO2024034593A1 (ja) Ｇ１２ｖ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
WO2024067714A1 (zh) 具有抗kras突变肿瘤活性的化合物
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
JP7724392B1 (ja) Ｋｒａｓタンパクの分解を誘導するための複素環化合物
JP7733274B1 (ja) Ｇ１２ｄ変異ｋｒａｓ阻害活性を有する二官能性化合物を含む抗がん剤の組合せ
JP7851842B2 (ja) Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物
HK40096919A (zh) 用於诱导g12d突变kras蛋白分解的喹唑啉化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150